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In isolated rat adipocytes, basal as well as insulin-stimulated 3-O-methylglucose transport was inhibited nearly completely 
(maximal inhibition: 95%) by the nucleoside transport inhibitors dipyridamole (IC,, = 5 PM), nitrobenzylthioguanosine 
(20 PM), nitrobenzylthioinosine (35 PM) and papaverine (130 PM). Transport kinetics in the presence of 10 PM dipyr- 
idamole revealed a significant increase in the transport K,,, value of 3-O-methylglucose (3.45 & 0.6 vs 2.36 & 0.29 mM in 
the controls) as well as a decrease in the V,,,,, value (4.84kO.95 vs 9.03 f 1.19 pmol/s per ~1 lipid in the controls). Half- 
maximally inhibiting concentrations of dipyridamole were one order of magnitude higher than those inhibiting nucleoside 
(thymidine) uptake (0.48 PM). The inhibitory effect of dipyridamole (5 PM) reached its maximum within 30 s. The agent 
failed to affect insulin’s half-maximally stimulating concentration (0.075 nM) indicating that it did not interfere with the 
mechanism by which insulin stimulates glucose transport. Further, dipyridamole fully suppressed the glucose-inhibitable 
cytochalasin B binding (IC,, = 1.65+0.05 PM). The data indicate that nucleoside transport inhibitors reduce glucose 
transport by a direct interaction with the transporter or a closely related protein. It is suggested that glucose and nucleos- 
ide transporters share structural, and possibly functional, features. 
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1. INTRODUCTION 
Several lines of evidence have suggested that the 
carrier proteins mediating facilitated diffusion of 
glucose and nucleosides hare functional and struc- 
tural characteristics. In human erythrocytes, both 
transporters are band 4.5 membrane proteins [ 1,2]. 
Copurification of both transport systems has been 
reported in these cells: the purified preparations 
contained binding activities of both nitroben- 
zylthioinosine and cytochalasin B, inhibitors of 
nucleoside and glucose transport, respectively 
[ 1,3]. Further, reconstitution experiments revealed 
that the purified material contained stereospecific 
glucose transport activity as well as nucleoside 
transport activity [4,5]. In addition, attempts to 
label the nucleoside transporter with a photoactive 
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derivative appeared to result in labeling of the 
glucose transporter [6]. 
In the present study, we tested the possibility 
that glucose and nucleoside transport can be dif- 
ferentiated with the aid of agents assumed to 
specifically inhibit the nucleoside transport. The 
results indicate that inhibitors of nucleoside 
transport are also potent inhibitors of glucose 
transport in rat adipose cells. The data suggest 
structural similarities, and possibly a functional 
relation, between the nucleoside transporter and 
the insulin-sensitive hexose transporter in adipose 
cells. Part of the results have been published in 
abstract form [7]. 
2. MATERIALS AND METHODS 
2.1. Materials 
3-O-[‘H]Methylglucose, [‘Hlthymidine and [‘Hlcytochalasin 
B were purchased from Amersham (Braunschweig, FRG). 
Dipyridamole was a gift from Dr Karl Thomae GmbH 
(Biberach, FRG). Nitrobenzylthioinosine (NBTI), nitroben- 
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zylthioguanosine (NBTG) and papaverine were supplied by 
Sigma (Deisenhofen, FRG). Crude bacterial collagenase was 
obtained from Cooper Biochemical; bovine serum albumin 
(fraction V) was from Serva (Heidelberg, FRG). 
2.2. Glucose transport 
Adipose cells were prepared from epididymal fat pads of 
male Wistar rats according to the method of Rodbell [8] with 
minor modifications [9]. Cells were incubated in a Krebs-Ringer 
Hepes buffer at 37°C with the agents under investigation. 
Where indicated, a preincubation period of 20 min with insulin 
in a concentration of 0.8 nM was performed in order to pro- 
duce maximal activation of glucose transport. Glucose 
transport activity was determined with the aid of the non- 
metabolizable hexose, 3-0methylglucose as described [9]. ln- 
itial methylglucose uptake rates were calculated as described in 
[lo]. All data were normalized per volume of lipid which was 
determined with the cytocrit method as described [ll]. Cell 
count was determined in parallel samples, and 1 pl of lipid 
routinely contained 10000 cells. 
2.3. Nucleoside transport 
Thymidine uptake was determined at a substrate concentra- 
tion of lOrM, which is approximately one tenth of the 
transport K,,, value in adipocytes (Steinfelder, unpublished). 
Isolated adipocytes at a cytocrit of lo-15% were incubated for 
20-30 min prior to the assay. Uptake was initiated by the addi- 
tion of [‘Hlthymidine (final concentration 10 PM; 0.5 &i), and 
the reaction was stopped after 15 s by the addition of 6.5 ml of 
a cold phloretin solution (0.3 mM, pH 7.4). Cells were 
separated from medium by centrifugation through silicone oil 
(density 0.96) within 3 min after termination of uptake. 
Equilibrium uptake was measured after incubation of the cells 
with the tritiated nucleoside for 1 h. After 15 s, about 30-40% 
of the equilibrium distribution space of the nucleoside were 
filled. The initial uptake rate vi was calculated from the uptake 
rates CJt and U,, as described for methylglucose uptake in [lo]. 
3. RESULTS 
3.1. Effect of nucleoside transport inhibitors on 
insulin-stimulated glucose transport 
Fig.1 illustrates the inhibitory effect of 
nucleoside transport inhibitors on the initial 3-0- 
methylglucose uptake rate in insulin-stimulated 
adipocytes. Isolated adipocytes were incubated 
with insulin (4.8 ng/ml) for 30 min, and the in- 
dicated concentrations of dipyridamole, papaver- 
ine, NBTI, or NBTG were added. After an ad- 
ditional incubation period of 5 min, methylglucose 
uptake was assayed as described in section 2. The 
agents inhibited the initial uptake rate of methyl- 
glucose in a concentration-dependent manner 
(fig.1). The maximal transport inhibition (approx. 
95%) was very similar for all four agents, but 
significant differences in the ICSO values were 
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Fig. 1. Inhibitory effect of nucleoside transport inhibitors on 
insulin-stimulated 30methylglucose transport in isolated 
adipocytes. Dipyridamole (o), nitrobenzyltbioinosine (o), 
nitrobenzylthioguanosine (0) and papaverine (m) were added 
5 min prior to the transport assay. Data represent he means of 
4 separate experiments. The mean control transport rate was 
0.333 + 0.015 pmol/s per pl lipid. 
observed. The order of potency was: dipyridamole 
(ICso = 5.1 + 0.8 PM) > NBTG (21.4 + 2.1 PM) > 
NBTI (36.4 k 8.2pM) * papaverine (130 + 
13 PM). Since dipyridamole was the most potent 
inhibitor, all further experiments were performed 
with this agent. 
Transport inhibition observed in the presence of 
dipyridamole (5 PM) was not dependent on the 
order of addition of insulin and the inhibitor: the 
magnitude of inhibition was the same when the 
agent was added after (5 or 15 min) or 
simultaneously with insulin (not shown). A study 
of the time course of the effect of dipyridamole 
(5 PM) revealed that the inhibition approached its 
maximum 30 s after addition of the agent (not 
shown). 
Fig.2 illustrates a series of experiments in which 
the concentration of insulin was varied. 
Dipyridamole reduced the initial methylglucose 
uptake rate by 35-45% at all tested concentrations 
of insulin. However, the concentration of insulin 
necessary to produce a half-maximal stimulation 
of glucose transport was not affected by the 
presence of 5 ,uM dipyridamole [0.072 + 0.018 nM 
(0.43 f 0.11 ng/ml) vs 0.077 f 0.008 nM (0.46 + 
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Fig.2. Concentration-dependent stimulation of glucose 
transport by insulin as measured in the presence (0) and 
absence (0) of dipyridamole (5 PM). The inhibitor was added 
together with the hormone at the start of the incubation. The 
transport assay was performed after 30 min of incubation at 
37°C. Data represent the mean + SE of 6 experiments. 
0.05 ng/ml) in control cells]. Thus, dipyridamole 
failed to alter the sensitivity of the cells to insulin. 
In a separate series of experiments the concen- 
tration dependence of the effect of dipyridamole 
was studied in basal adipocytes (not shown). The 
ICSO of the transport inhibitor was 7.1 -t 1 .O ,uM 
(n = 4) in basal cells as compared with 5.1 +- 
0.8 ,uM in insulin-stimulated adipocytes (n = 4), in- 
dicating that insulin treatment of cells does not 
significantly alter the sensitivity of the cells to 
dipyridamole. 
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Fig.3. Concentration-dependent inhibition of the D-glucose 
inhibitable [3H]cytochalasin B binding by dipyridamole in 
plasma membranes of insulin-stimulated adipocytes. ICsc = 
1.65 + 0.05 ,uM. Data are means of 4 experiments. 
3.2. Transport kinetics in the presence of 
dipyridamole (IO @I,) 
In order to define the type of inhibition, the 
substrate dependence of insulin-stimulated glucose 
transport was studied in the presence and absence 
of dipyridamole (10 ,uM). V,,,,, and K,,, values ob- 
tained from Hanes plots are given in table 1. The 
data indicated that dipyridamole significantly af- 
fected the transport V,,, value (45% inhibition) as 
well as the transport K, value (45% increase). 
Therefore, dipyridamole appeared to inhibit 
glucose transport in an uncompetitive manner. 
3.3. Effect of dipyridamole on cytochalasin B 
binding 
Cytochalasin B is considered to be a specific 
ligand for the glucose transporter [2,12,13]. In an 
attempt to demonstrate a direct interaction of 
nucleoside transport inhibitors with the glucose 
transporter, the effect of dipyridamole on 
cytochalasin B binding was studied. Most non- 
specific binding sites were blocked with 
cytochalasin E as described [14], and the residual 
non-specific binding was assessed with samples in- 
cubated in the presence of 200 mM D-glucose. 
Fig.3 illustrates that dipyridamole fully displaced 
the glucose-inhibitable cytochalasin B binding in 
plasma membranes from insulin-treated adipo- 
cytes with an 1Cs0 of 1.65 f 0.05 PM. 
3.4. Effect of dipyridamole on nucleoside 
transport in rat adipocytes 
In order to compare the effects of dipyridamole 
Table 1 
Kinetic parameters of insulin-stimulated glucose transport in 
the absence and presence of dipyridamole (10 PM) 
V 
(pmoiZ per 
,LLI lipid) 
(ZI) 
Control 9.03 & 1.19 2.36 + 0.29 
Dipyridamole (10 PM) 4.84 + 0.95 3.45 + 0.60 
Methylglucose uptake was assayed in cells pretreated with a 
maximally effective concentration of insulin at 5 different 
substrate concentrations. For kinetic evaluation the transport 
data were transformed in a Hanes plot, and values of V,,,, and 
K, of the individual experiments were determined by linear 
regression. Data given are the means + SE of 4 separate 
experiments 
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Fig.4. Comparison of the effects of dipyridamole on thymidine 
and 3-0-methylglucose transport in isolated adipocytes. Cells 
were incubated with 4.8 ng/ml insulin for 30 min prior to the 
transport assays. Data are the means of 4 experiments. Half- 
maximally inhibiting concentrations of dipyridamole were 
0.48 * 0.11 pM (thymidine uptake) and 5.25 + 0.63pM 
(glucose transport). 
on glucose transport with those on nucleoside 
transport, [3H]thymidine uptake was studied in 
isolated adipocytes. In preliminary experiments it 
was ascertained that thymidine uptake in 
adipocytes was a saturable process and that no 
metabolism of the nucleoside occurred (not 
shown). Thus thymidine appeared to be the most 
suitable substrate for the study of nucleoside 
transport in these cells. Fig.4 illustrates that the 
dipyridamole concentrations inhibiting uptake of 
the nucleoside (IGO = 0.48 + 0.11 PM) were about 
one order of magnitude lower than those reducing 
glucose transport in insulin-stimulated cells (IGO = 
5.25 + 0.63rM). 
4. DISCUSSION 
The present data indicate that nucleoside 
transport inhibitors also interfere with the insulin- 
dependent glucose transport in adipocytes. Our 
findings suggest hat both transport systems hare 
structural, and probably functional, character- 
istics. This conclusion is supported by the recent 
findings of Jarvis et al. [6] who showed that the 
adenosine derivative &zidoadenosine, which was 
initially used as a photoaffinity probe of the 
nucleoside transporter [15], appeared to label 
mainly the glucose transporter in human ery- 
throcytes [6]. However, the present data indicate 
that the concentrations required for glucose 
transport inhibition were approximately one order 
of magnitude higher than those necessary for 
nucleoside transport inhibition. Thus, the site 
responsible for mediating the effect of the in- 
hibitors may be structurally similar, but cannot be 
identical in both transporters. It should be noted, 
that nucleoside transport appears to be less sen- 
sitive to inhibitors in rat adipocytes than in human 
erythrocytes [l] and in S49 mouse lymphoma cells 
[16], because the ICSO values reported in these 
studies were lower than those observed here. 
Three lines of evidence suggest hat the agents 
interact directly with the transporter or a closely 
related protein. First, the nucleoside transport in- 
hibitors appeared not to interfere with the 
mechanism by which insulin activates transport. 
Both basal and insulin-stimulated transport were 
inhibited, and the sensitivity of cells to insulin 
(EGO) was unaffected by the agents. Second, the 
nucleoside transport inhibitor dipyridamole fully 
abolished the glucose-inhibitable component of 
cytochalasin B binding which is considered to 
reflect a binding site at the glucose transporter 
[2,12,14]. It has been reported that nucleosides in- 
terfered with the binding of cytochalasin B to 
plasma membranes of human erythrocytes [6]. 
Since cytochalasin B was a poor inhibitor of 
nucleoside transport in reconstitution experiments 
[5], and is therefore unlikely to bind to the 
nucleoside transporter, this finding suggested that 
nucleosides interact with the glucose transporter 
which is an abundant protein in erythrocyte mem- 
branes [17]. Third, the agents inhibited glucose 
transport within seconds after addition to the cells. 
This rapid onset of action is in marked contrast to 
the slower onset (half time 3-6 min) of the effects 
produced by catecholamines [18], ACTH [9] and 
insulin [19]. 
Kinetic experiments indicated an uncompetitive 
type of inhibition with alteration of both K,,, and 
VmaX values. Thus the nucleoside transport in- 
hibitors do not appear to block the site that 
recognizes the glucose molecule. This mechanism 
has been suggested for the inhibitory effect of for- 
skolin on glucose transport on the basis of data 
showing a competitive type of inhibition [lo]. On 
the basis of the present data it cannot be excluded, 
therefore, that the binding site for the nucleoside 
transport inhibitors is not located at the glucose 
transporter but at a regulatory protein interacting 
with the transporter. 
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In summary, the glucose and the nucleoside 
transporter share a similar binding site through 
which transport is inhibited. Thus, the comparison 
of the two transport systems might allow elucida- 
tion of the molecular basis of their function. 
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